Chemistry:Telisotuzumab vedotin

From HandWiki

Telisotuzumab vedotin is a monoclonal antibody developed by AbbVie for non-small cell lung cancer.[1][2][3][4][5]

References

  1. ↑ Camidge, D. Ross; Barlesi, Fabrice; Goldman, Jonathan W.; Morgensztern, Daniel; Heist, Rebecca; Vokes, Everett; Spira, Alex; Angevin, Eric et al. (10 February 2023). "Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer". Journal of Clinical Oncology 41 (5): 1105–1115. doi:10.1200/JCO.22.00739. ISSN 0732-183X. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928626/. 
  2. ↑ Fujiwara, Yutaka; Kenmotsu, Hirotsugu; Yamamoto, Noboru; Shimizu, Toshio; Yonemori, Kan; Ocampo, Christopher; Parikh, Apurvasena; Okubo, Sumiko et al. (April 2021). "Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors" (in en). Cancer Medicine 10 (7): 2350–2358. doi:10.1002/cam4.3815. ISSN 2045-7634. PMC 7982615. https://doi.org/10.1002/cam4.3815. 
  3. ↑ Camidge, D. Ross; Barlesi, Fabrice; Goldman, Jonathan W.; Morgensztern, Daniel; Heist, Rebecca; Vokes, Everett; Angevin, Eric; Hong, David S. et al. (January 2022). "A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC". JTO Clinical and Research Reports 3 (1): 100262. doi:10.1016/j.jtocrr.2021.100262. 
  4. ↑ Waqar, Saiama N.; Redman, Mary W.; Arnold, Susanne M.; Hirsch, Fred R.; Mack, Philip C.; Schwartz, Lawrence H.; Gandara, David R.; Stinchcombe, Thomas E. et al. (1 May 2021). "A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)". Clinical Lung Cancer 22 (3): 170–177. doi:10.1016/j.cllc.2020.09.013. ISSN 1525-7304. PMC 8044254. https://www.sciencedirect.com/science/article/abs/pii/S152573042030293X. 
  5. ↑ Strickler, John H.; Weekes, Colin D.; Nemunaitis, John; Ramanathan, Ramesh K.; Heist, Rebecca S.; Morgensztern, Daniel; Angevin, Eric; Bauer, Todd M. et al. (20 November 2018). "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors". Journal of Clinical Oncology 36 (33): 3298–3306. doi:10.1200/jco.2018.78.7697. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Telisotuzumab_vedotin&oldid=3334074"